OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
William W. Busse, Sheldon L. Spector, Karin Rosén, et al.
Journal of Allergy and Clinical Immunology (2013) Vol. 132, Iss. 2, pp. 485-486.e11
Open Access | Times Cited: 152
William W. Busse, Sheldon L. Spector, Karin Rosén, et al.
Journal of Allergy and Clinical Immunology (2013) Vol. 132, Iss. 2, pp. 485-486.e11
Open Access | Times Cited: 152
Showing 1-25 of 152 citing articles:
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Fernando Holguín, Juan Carlos Cardet, Kian Fan Chung, et al.
European Respiratory Journal (2019) Vol. 55, Iss. 1, pp. 1900588-1900588
Open Access | Times Cited: 495
Fernando Holguín, Juan Carlos Cardet, Kian Fan Chung, et al.
European Respiratory Journal (2019) Vol. 55, Iss. 1, pp. 1900588-1900588
Open Access | Times Cited: 495
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
Ioana Agache, Jessica Beltrán, Cezmi A. Akdiş, et al.
Allergy (2020) Vol. 75, Iss. 5, pp. 1023-1042
Open Access | Times Cited: 321
Ioana Agache, Jessica Beltrán, Cezmi A. Akdiş, et al.
Allergy (2020) Vol. 75, Iss. 5, pp. 1023-1042
Open Access | Times Cited: 321
Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology
Antonella Muraro, Robert F. Lemanske, Peter W. Hellings, et al.
Journal of Allergy and Clinical Immunology (2016) Vol. 137, Iss. 5, pp. 1347-1358
Open Access | Times Cited: 273
Antonella Muraro, Robert F. Lemanske, Peter W. Hellings, et al.
Journal of Allergy and Clinical Immunology (2016) Vol. 137, Iss. 5, pp. 1347-1358
Open Access | Times Cited: 273
Evolving Concepts of Asthma
Marc Gauthier, Anuradha Ray, Sally E. Wenzel
American Journal of Respiratory and Critical Care Medicine (2015) Vol. 192, Iss. 6, pp. 660-668
Open Access | Times Cited: 239
Marc Gauthier, Anuradha Ray, Sally E. Wenzel
American Journal of Respiratory and Critical Care Medicine (2015) Vol. 192, Iss. 6, pp. 660-668
Open Access | Times Cited: 239
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
Thomas B. Casale, Allan T. Luskin, William W. Busse, et al.
The Journal of Allergy and Clinical Immunology In Practice (2018) Vol. 7, Iss. 1, pp. 156-164.e1
Open Access | Times Cited: 232
Thomas B. Casale, Allan T. Luskin, William W. Busse, et al.
The Journal of Allergy and Clinical Immunology In Practice (2018) Vol. 7, Iss. 1, pp. 156-164.e1
Open Access | Times Cited: 232
High Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma
Robert S. Zeiger, Michael Schatz, Qiaowu Li, et al.
The Journal of Allergy and Clinical Immunology In Practice (2014) Vol. 2, Iss. 6, pp. 741-750.e4
Closed Access | Times Cited: 221
Robert S. Zeiger, Michael Schatz, Qiaowu Li, et al.
The Journal of Allergy and Clinical Immunology In Practice (2014) Vol. 2, Iss. 6, pp. 741-750.e4
Closed Access | Times Cited: 221
EAACI Biologicals Guidelines—Recommendations for severe asthma
Ioana Agache, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Allergy (2020) Vol. 76, Iss. 1, pp. 14-44
Open Access | Times Cited: 217
Ioana Agache, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Allergy (2020) Vol. 76, Iss. 1, pp. 14-44
Open Access | Times Cited: 217
Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?
Andrea Matucci, Alessandra Vultaggio, Enrico Maggi, et al.
Respiratory Research (2018) Vol. 19, Iss. 1
Open Access | Times Cited: 183
Andrea Matucci, Alessandra Vultaggio, Enrico Maggi, et al.
Respiratory Research (2018) Vol. 19, Iss. 1
Open Access | Times Cited: 183
Asthma Endotyping and Biomarkers in Childhood Asthma
Amelia Licari, Riccardo Castagnoli, Ilaria Brambilla, et al.
Pediatric Allergy Immunology and Pulmonology (2018) Vol. 31, Iss. 2, pp. 44-55
Open Access | Times Cited: 155
Amelia Licari, Riccardo Castagnoli, Ilaria Brambilla, et al.
Pediatric Allergy Immunology and Pulmonology (2018) Vol. 31, Iss. 2, pp. 44-55
Open Access | Times Cited: 155
A Pilot Study of Omalizumab in Eosinophilic Esophagitis
Denise Loizou, Benjamin Enav, Edina Komlódi-Pásztor, et al.
PLoS ONE (2015) Vol. 10, Iss. 3, pp. e0113483-e0113483
Open Access | Times Cited: 146
Denise Loizou, Benjamin Enav, Edina Komlódi-Pásztor, et al.
PLoS ONE (2015) Vol. 10, Iss. 3, pp. e0113483-e0113483
Open Access | Times Cited: 146
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Thomas B. Casale, Bradley E. Chipps, Karin Rosén, et al.
Allergy (2017) Vol. 73, Iss. 2, pp. 490-497
Open Access | Times Cited: 143
Thomas B. Casale, Bradley E. Chipps, Karin Rosén, et al.
Allergy (2017) Vol. 73, Iss. 2, pp. 490-497
Open Access | Times Cited: 143
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Kenneth R. Chapman, Frank C. Albers, Bradley E. Chipps, et al.
Allergy (2019) Vol. 74, Iss. 9, pp. 1716-1726
Open Access | Times Cited: 139
Kenneth R. Chapman, Frank C. Albers, Bradley E. Chipps, et al.
Allergy (2019) Vol. 74, Iss. 9, pp. 1716-1726
Open Access | Times Cited: 139
Characterization of asthma endotypes: implications for therapy
Jeffrey R. Stokes, Thomas B. Casale
Annals of Allergy Asthma & Immunology (2016) Vol. 117, Iss. 2, pp. 121-125
Closed Access | Times Cited: 106
Jeffrey R. Stokes, Thomas B. Casale
Annals of Allergy Asthma & Immunology (2016) Vol. 117, Iss. 2, pp. 121-125
Closed Access | Times Cited: 106
Anti‐IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss): Data on Seventeen Patients
M. Jachiet, Maxime Samson, Vincent Cottin, et al.
Arthritis & Rheumatology (2016) Vol. 68, Iss. 9, pp. 2274-2282
Closed Access | Times Cited: 97
M. Jachiet, Maxime Samson, Vincent Cottin, et al.
Arthritis & Rheumatology (2016) Vol. 68, Iss. 9, pp. 2274-2282
Closed Access | Times Cited: 97
Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects
Fanny Legrand, Amy D. Klion
The Journal of Allergy and Clinical Immunology In Practice (2015) Vol. 3, Iss. 2, pp. 167-174
Open Access | Times Cited: 96
Fanny Legrand, Amy D. Klion
The Journal of Allergy and Clinical Immunology In Practice (2015) Vol. 3, Iss. 2, pp. 167-174
Open Access | Times Cited: 96
Severe asthma and quality of life
Elham Hossny, Luis Caraballo, Thomas B. Casale, et al.
World Allergy Organization Journal (2017) Vol. 10, pp. 28-28
Open Access | Times Cited: 95
Elham Hossny, Luis Caraballo, Thomas B. Casale, et al.
World Allergy Organization Journal (2017) Vol. 10, pp. 28-28
Open Access | Times Cited: 95
Severe Asthma and Biological Therapy: When, Which, and for Whom
Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, et al.
Pulmonary Therapy (2019) Vol. 6, Iss. 1, pp. 47-66
Open Access | Times Cited: 86
Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, et al.
Pulmonary Therapy (2019) Vol. 6, Iss. 1, pp. 47-66
Open Access | Times Cited: 86
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison
Andrew Menzies‐Gow, Jason Steenkamp, Sumeet Singh, et al.
Journal of Medical Economics (2022) Vol. 25, Iss. 1, pp. 679-690
Open Access | Times Cited: 39
Andrew Menzies‐Gow, Jason Steenkamp, Sumeet Singh, et al.
Journal of Medical Economics (2022) Vol. 25, Iss. 1, pp. 679-690
Open Access | Times Cited: 39
Cytokine-targeted therapies for asthma and COPD
Florence Schleich, Nicolas Bougard, Catherine Moermans, et al.
European Respiratory Review (2023) Vol. 32, Iss. 168, pp. 220193-220193
Open Access | Times Cited: 37
Florence Schleich, Nicolas Bougard, Catherine Moermans, et al.
European Respiratory Review (2023) Vol. 32, Iss. 168, pp. 220193-220193
Open Access | Times Cited: 37
New and future strategies to improve asthma control in children
William Anderson, Stanley J. Szefler
Journal of Allergy and Clinical Immunology (2015) Vol. 136, Iss. 4, pp. 848-859
Open Access | Times Cited: 87
William Anderson, Stanley J. Szefler
Journal of Allergy and Clinical Immunology (2015) Vol. 136, Iss. 4, pp. 848-859
Open Access | Times Cited: 87
Biologic Therapy and Novel Molecular Targets of Severe Asthma
Amber N. Pepper, Harald Renz, Thomas B. Casale, et al.
The Journal of Allergy and Clinical Immunology In Practice (2017) Vol. 5, Iss. 4, pp. 909-916
Closed Access | Times Cited: 80
Amber N. Pepper, Harald Renz, Thomas B. Casale, et al.
The Journal of Allergy and Clinical Immunology In Practice (2017) Vol. 5, Iss. 4, pp. 909-916
Closed Access | Times Cited: 80
Utility of serum periostin and free I gE levels in evaluating responsiveness to omalizumab in patients with severe asthma
Tomoko Tajiri, Hisako Matsumoto, Yasuhiro Gon, et al.
Allergy (2016) Vol. 71, Iss. 10, pp. 1472-1479
Closed Access | Times Cited: 76
Tomoko Tajiri, Hisako Matsumoto, Yasuhiro Gon, et al.
Allergy (2016) Vol. 71, Iss. 10, pp. 1472-1479
Closed Access | Times Cited: 76
Biologics in Asthma—The Next Step Toward Personalized Treatment
Jared I. Darveaux, William W. Busse
The Journal of Allergy and Clinical Immunology In Practice (2015) Vol. 3, Iss. 2, pp. 152-160
Open Access | Times Cited: 75
Jared I. Darveaux, William W. Busse
The Journal of Allergy and Clinical Immunology In Practice (2015) Vol. 3, Iss. 2, pp. 152-160
Open Access | Times Cited: 75
Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD
Κonstantinos Κostikas, Caterina Brindicci, Francesco Patalano
Current Drug Targets (2018) Vol. 19, Iss. 16, pp. 1882-1896
Open Access | Times Cited: 73
Κonstantinos Κostikas, Caterina Brindicci, Francesco Patalano
Current Drug Targets (2018) Vol. 19, Iss. 16, pp. 1882-1896
Open Access | Times Cited: 73
The discovery and development of omalizumab for the treatment of asthma
Amelia Licari, Gian Luigi Marseglia, Riccardo Castagnoli, et al.
Expert Opinion on Drug Discovery (2015) Vol. 10, Iss. 9, pp. 1033-1042
Closed Access | Times Cited: 72
Amelia Licari, Gian Luigi Marseglia, Riccardo Castagnoli, et al.
Expert Opinion on Drug Discovery (2015) Vol. 10, Iss. 9, pp. 1033-1042
Closed Access | Times Cited: 72
